Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Research & Development: 2018-2024

Historic Research & Development for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to $67.9 million.

  • Silence Therapeutics' Research & Development rose 1.91% to $20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.1 million, marking a year-over-year decrease of 43.20%. This contributed to the annual value of $67.9 million for FY2024, which is 19.22% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Research & Development is $67.9 million, which was up 19.22% from $56.9 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Research & Development peaked at $67.9 million during FY2024, and registered a low of $26.0 million during FY2020.
  • For the 3-year period, Silence Therapeutics' Research & Development averaged around $56.1 million, with its median value being $56.9 million (2023).
  • Data for Silence Therapeutics' Research & Development shows a peak YoY surged of 63.11% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Silence Therapeutics' Research & Development stood at $26.0 million in 2020, then soared by 63.11% to $42.3 million in 2021, then climbed by 2.88% to $43.5 million in 2022, then skyrocketed by 30.74% to $56.9 million in 2023, then grew by 19.22% to $67.9 million in 2024.